NCT07146880View on ClinicalTrials.gov

Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

August 21, 2027

Study Completion Date

September 21, 2027

Conditions
Brugada Syndrome (BrS)
Interventions
DRUG

Empagliflozin (EMPA)

Participants will take Empagliflozin once daily, starting at 10 mg. The dose will be increased to 25 mg at monthly follow-ups if participants are non-responders based on ECG ST-segment morphology. The total treatment period is three months.

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

Stanford University

OTHER

lead

National Taiwan University Hospital

OTHER

NCT07146880 - Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome | Biotech Hunter | Biotech Hunter